KRAS and non-small cell lung carcinoma: The EGFR signaling pathway is among the most important drivers of lung tumorigenesis: mutations in EGFR (10–15%) or mutations or translocations of downstream effectors including KRAS (25–40%) and ALK (5–7%) are frequently found in Caucasian NSCLC patients [7].